Conventional Treatment of Systemic Lupus Erythematosus

Giacomo Quattrocchio, Fernando Fervenza, Dario Roccatello

Research output: Chapter in Book/Report/Conference proceedingChapter


Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with unpredictable course, intermingled with flares and periods of remission. The treatment target of SLE should be remission of systemic symptoms and organ manifestations or attainment of the lowest possible disease activity, measured by at least one validated disease activity index and/or by organ-specific markers. Although the prognosis of the disease has improved in the past decades, current therapies are still associated with treatment-related complications. Moreover, each patient may manifest different symptoms and variable disease activity and severity, as well as therapy-related adverse effects. SLE patients frequently have numerous comorbidities, such as hyperlipidemia and hypertension, which represent risk factors for accelerated atherosclerosis and cardiovascular disease and depression, which can seriously compromise health-related quality of life. This chapter focuses on conventional management of SLE patients, including nonpharmacologic measures and pharmacological therapies.

Original languageEnglish (US)
Title of host publicationRare Diseases of the Immune System
PublisherSpringer Nature
Number of pages26
StatePublished - 2016

Publication series

NameRare Diseases of the Immune System
ISSN (Print)2282-6505
ISSN (Electronic)2283-6403


  • Glucocorticoids
  • Hydroxychloroquine
  • Immunosuppression
  • Systemic lupus erythematosus
  • Target therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Genetics(clinical)


Dive into the research topics of 'Conventional Treatment of Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this